spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines
King Pharmaceuticals is a vertically integrated pharmaceutical company that manufactures, markets, and sells primarily branded prescription pharmaceutical products. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry created by cost containment initiatives and consolidation among large global pharmaceutical companies. King's strategy is to acquire branded pharmaceutical products and to increase their sales by focused promotion and marketing and through product life cycle management.

Bristol, Tennessee

Eli Lilly and Company Eli Lilly and Company creates and delivers innovative medicines that enable people to live longer, healthier and more active lives. Lilly products treat depression, schizophrenia, diabetes, cancer, osteoporosis and many other diseases. They create value for patients, health-care providers and payers, and reduce the cost of disease.

Indianapolis, Indiana

Ligand is an emerging specialty pharmaceutical company that discovers, develops and markets innovative small molecule drugs to address critical, unmet medical needs.

San Diego, California

LigoCyte, established in 1998, focuses on cell-surface receptors that govern the way the human immune system recognizes and responds to inflammatory events and infectious organisms. The company's immunomodulatory drug discovery and development activities support its pipeline of therapeutic candidates. LigoCyte has developed the ProteoFlow® high content assay technology for the evaluation of inhibitors in human cells under physiologic flow conditions. This powerful technology provides the company with a highly effective tool for predicting drug behavior in animals and humans, streamlining the drug development process and reducing risk associated with dosing efficacy.

920 Technology Boulevard, Suite C
Bozeman, Montana 59718
  406-585-2733
  ligocyte@ligocyte.com

Mallinckrodt, Inc. Tyco Healthcare, based in St. Louis, Missouri, manufactures and markets medical products. Our mission is to improve healthcare for patients worldwide by providing superior products that sustain breathing, diagnose disease and relieve pain. We are committed to producing products that bring better healthcare to patients, more value to medical professionals, greater opportunity to employees, and increased earnings to reward Tyco shareholders.

Hazelwood, Missouri

Maxim Pharmaceuticals is a global bio-pharmaceutical company with a diverse pipeline of therapeutic candidates for life-threatening cancers, hepatitis and other liver diseases.

San Diego, California

MedImmune, Inc. is a fully integrated biotechnology company founded in 1988. It is focused on developing and marketing products that address medical needs in areas such as infectious disease, immune regulation, and cancer. The company's capabilities span the entire spectrum of pharmaceutical development, including discovery research, clinical development, data analysis, regulatory affairs, quality control, manufacturing, and sales and marketing.

Gaithersburg, Maryland

Memory Pharmaceuticals, a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer’s Disease, depression, schizophrenia, vascular dementia, Mild Cognitive Impairment, and memory impairments associated with aging. The Company’s customized drug development infrastructure emphasizes rigorous target identification and compound screening procedures, medicinal chemistry, neurobehavioral biology, and sophisticated IT systems. Advanced capabilities and in-house expertise in drug discovery and development have allowed the Company to generate a diverse pipeline of promising drug development programs.

100 Philips Parkway
Montvale, New Jersey 07645
  (201) 802-7100
  info@memorypharma.com

Merck & Company, Inc. Merck & Co., Inc. is a leading research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health. The Merck-Medco Managed Care Division manages pharmacy benefits for more than 40 million Americans, encouraging the appropriate use of medicines and providing disease management programs.

Whitehouse Station, New Jersey

Millennium Pharmaceuticals currently markets two products, the cardiovascular drug INTEGRILIN® (eptifibatide) Injection and the oncology drug VELCADE™ (bortezomib) for Injection. These are examples of the types of drugs Millennium expects to develop in four key therapeutic areas:
  • Cancer
  • Cardiovascular diseases
  • Inflammation
  • Metabolic disorders
The company also has a significant number of investigational drugs at various stages of clinical and preclinical development, as described in the R&D section of this website, and played a significant role in bringing the oncology drug Campath® (alemtuzumab) Injection to market.

Cambridge, Massachusetts
  info@mlnm.com

Miravant Medical Technologies specializes in pharmaceuticals and devices for photoselective medicine, developing its proprietary PhotoPoint photodynamic therapy (PDT) for large potential markets in ophthalmology, dermatology, cardiovascular disease and oncology. PhotoPoint PDT uses photoreactive (light-activated) drugs to selectively target diseased cells and blood vessels.

336 Bollay Drive
Santa Barbara, California 93117
  805.685.9880
  info@miravant.com

Mölnlycke Health Care is one of the world’s leading manufacturers of single-use surgical products – patient drapes, instrument drapes and surgical gowns, caps and masks for operating staff. The group also has a strong international standing in the professional wound care sector, with a wide range of products for the treatment of surgical wounds, chronic wounds and burns. Total annual sales are at present SEK 4,500M and the company has app. 4,000 employees. Of these, about 3,300 are involved in production at factories in Belgium, Finland, Mexico, Thailand and Czech Republic. Headquarters in Göteborg, Sweden is home to all group staff functions as well as business area management, sales management and Global Supply, which includes, e.g procurement, logistics and IT. The major shareholders in Mölnlycke Health Care are Nordic Capital and the Sixth National Pension Fund. Two business areas: Operations are divided into two business areas – Surgical and Wound Care. Surgical business area products are sold under the brand names Klinidrape® and BARRIER®. Wound Care business area products are sold under the Tendra® brand. Sales and marketing: Sales and marketing of both business areas are the responsibility of three joint organisations, one for the US, one for Europe and one for other markets. Twenty subsidiaries and several branch sales offices and distributors are included in the organisation.

Goteborg, Sweden

Myconostica Ltd develops and supplies molecular diagnostic products to aid rapid and accurate diagnosis of life threatening invasive fungal infections. Myconostica have used advances in molecular techniques such as real time PCR to develop a range of assays for the rapid, accurate and sensitive detection of fungi such as Aspergillus spp and Pneumocystis. Evidence shows that an early diagnosis of invasive fungal infection significantly improves the chance of survival. Tests provided by Myconostica will aim to allow healthcare professionals to rapidly identify those patients infected by invasive fungal pathogens thus enabling clinicians to prescribe appropriate drug therapy. Early identification of disease reduces the hospitalisation and treatment costs associated with invasive fungal disease.

South Court, Sharston Road
Manchester, United Kingdom M22 4SN
  +44161 998 7239
  mycoinfo@myconostica.co.uk
Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary prescription products. Mylan markets its branded pharmaceuticals through Bertek Pharmaceuticals Inc. Bertek operates as a stand-alone proprietary pharmaceutical company with independent clinical development, business development and sales and marketing efforts. Bertek is a transitional pharmaceutical company that will enable Mylan to grow from a traditional generic company to a proprietary based company. The Company's strategy is to optimize marketing and sales through a targeted therapeutic focus on neurology, dermatology and cardiology, thereby enabling our field sales representatives to concentrate on a narrow physician call base, as well as developing new products as trading stock for other Bertek products. Bertek's vision is to be a growth oriented, highly profitable pharmaceutical company that efficiently commercializes significant improvements to human healthcare.

1500 Corporate Drive Suite 400
Canonsburg, Pennsylvania 15317
  724-514-1800
  customerservice@mylanlabs.com

NaPro BioTherapeutics, Inc., is a life science company focused in two distinct therapeutic areas: the development of proprietary anti-cancer agents and the development of genomic therapies for inherited disease, primarily through the use of our novel "gene editing" technology.

4840 Pearl East Circle, #300W
Boulder, Colorado 80301
  303 516-8500
  info@naprobio.com

Nektar Therapeutics (NASDAQ:NKTR) provides a portfolio of leading drug delivery solutions that enable the development of high-value pharmaceutical products. Formed through the fusion of Inhale Therapeutic Systems, Shearwater, and Bradford Particle Design, our company offers a suite of leading drug delivery technologies that encompasses molecule engineering including advanced pegylation, particle engineering comprising both pulmonary particle technology and supercritical fluid technology (SCF), and advanced drug delivery solutions for oral, injectable, and pulmonary administration.

San Carlos, California

NeoGenesis Pharmaceuticals, Inc. is a drug discovery company focused on using its proprietary drug discovery technologies to discover and develop a portfolio of small molecule-based drugs, both for itself and for its collaboration partners. The company's universal, unbiased, affinity-based technologies, coupled with millions of diverse medicinally relevant compounds, provide an unmatched efficiency in lead discovery and optimization. NeoGenesis' core technology, the Automated Ligand Identification System (ALIS), is a rapid and universal affinity-based system for identifying and optimizing novel drug leads. Coupled with the company's NeoMorph compound library, consisting of more than 10 million diverse medicinally relevant small molecules, ALIS enables the identification of novel and selective drug leads against validated and emerging new genomic targets.

840 Memorial Drive
Camgridge, Massachusetts 02139
  (617) 868-1500
  info@neogenesis.com

NeoRx is a cancer therapeutics company developing products for targeted delivery of anti-cancer agents, including radiopharmaceuticals, to tumor sites.

300 Elliott Avenue West, Suite 500
Seattle, Washington 98119
  206-281-7001
  IR@neorx.com

Neurion Pharmaceuticals, Inc. is a privately held, development-stage pharmaceutical company that is focused on the discovery of novel drugs for central nervous system (CNS) diseases and other disorders associated with ion channels. The Company uses its proprietary discovery platform technology to understand the structural basis of drug-ion channel interactions, and to design safer and more effective drugs by exploiting this knowledge.

180 North Vinedo Avenue
Pasadena, California 91107
  626-685-5977
  billr@neurionpharma.com

Neurocrine Biosciences is a biopharmaceutical company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The Company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, multiple sclerosis, insomnia, brain cancer, obesity and diabetes.

San Diego, California

Novartis Pharmaceuticals Novartis is a global company that touches your life in ways you might not have imagined. Our employees make products that range from life-saving drugs for organ transplantation to state-of-the-art contact lenses, from affordable generic medicines to a famous name in baby food, from trusted over-the-counter brands against the common cold to products that protect farm animals and your beloved pets from parasites and disease. What do these business areas have in common? They are all powered by science and innovation. Novartis invests approximately 4 billion Swiss francs every year in research and development. We are exploring new scientific horizons and applying the latest technologies to lead future breakthroughs.

New York, New York

Novo Nordisk is a focused healthcare company. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is the world leader in diabetes care. In addition, Novo Nordisk has a leading position in areas such as haemostasis management, growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.

Plantation, Florida

NPS Pharmaceuticals is engaged in the discovery and development, and is preparing for the commercialization of therapeutic small molecules and recombinant proteins. Current product candidates include treatments for bone and mineral disorders (osteoporosis & hyperparathyroidism), gastrointestinal disorders (GI) and central nervous system disorders (CNS). Our objective is to build a profitable company by using our scientific development and marketing expertise, which will allow us and the patients who use our drugs, to reap the value of our efforts. We are creating a diversified pipeline of products in all stages of development from discovery research, to preclinical testing, to clinical trials.

Salt Lake City, Utah

NutraDoc products are provided exclusively to medical professionals at wholesale rates, enabling you to sell top-quality products to your patients at reasonable prices. Because our entire process from research all the way through manufacturing and shipping is handled in-house, we can both guarantee quality and keep costs down.

Contact:
Bill Blish
Sr. VP of Sales
601 Cleveland Street
Clearwater, FL 33755
USA
  603 398-6807
  bblish@gfaproductioninc.com
Nymox Pharmaceutical Corporation is a biopharmaceutical company based in Maywood, New Jersey and Saint Laurent, Quebec. It has two subsidiaries, Nymox Corporation and Serex, Inc. Nymox specializes in the research and development of therapeutics and diagnostics for the aging population with an emphasis on Alzheimer's disease. Nymox was incorporated in 1989 and became a public company in 1995. Nymox was founded around a group of distinguished career scientists with long established interests in brain diseases and Alzheimer’s disease in particular. Nymox is the first company to have successfully developed an accurate peripheral test for this devastating disorder, the AlzheimAlert™ test. Nymox’s strong scientific relationships have led to the development every year of at least one major new project initiative. Nymox currently markets its AlzheimAlert™ test to physicians in the U.S. and its NicAlert™ test for tobacco exposure both in the U.S. and Japan. Nymox has an exciting pipeline of drugs in development and a proprietary antimicrobial treatment against deadly E. coli contamination. Nymox also has a line of other “Alert” products (such as OsteoAlert™ for osteoporosis) in development, as well as a unique proprietary diagnostic platform technology.

230 West Passaic Street
Maywood, New Jersey 07607
  (800) 936-9669
  info@nymox.com

Organon is a renowned global pharmaceuticals company with a strong commitment to human health care. The company develops and produces innovative prescription medicines for women's health, mental health, cardiovascular disease, immunology, and anesthesiology. Organon products are sold in over 100 countries, more than half of which have an Organon subsidiary. Organon was founded in 1923 and is a business unit of the Pharma division of Akzo Nobel, NV. The Pharma division consists of three business units – Organon, Intervet and Diosynth.

Roseland, New Jersey

Ortho-McNeil, a Johnson & Johnson company, is based in Raritan, NJ. The company markets pharmaceutical products in several therapeutic categories including infectious diseases, central nervous system, wound healing, urology and women's health.

Raritan, New Jersey

OSI Pharmaceuticals is a leading biotechnology company focused on the discovery, development, and commercialization of high-quality, next-generation oncology products that both extend and improve the quality-of-life for cancer patients worldwide. OSI has a balanced pipeline of oncology drug candidates that includes both next-generation cytotoxic agents and novel mechanism-based, gene-targeted therapeutics focused in the areas of signal transduction and apoptosis. OSI has a commercial presence in the U.S. oncology market where it exclusively markets Novantrone® (mitoxantrone concentrate for injection) for approved oncology indications and Gelclair(TM) for the relief of pain associated with oral mucositis. Our most advanced drug candidate is Tarceva™ (erlotinib HCl), a small-molecule inhibitor of the epidermal growth factor receptor, or HER1/EGFR. We believe HER1/EGFR inhibitors represent an exciting new class of relatively safe and well-tolerated anti-cancer agents that may have utility in treating a wide range of cancer patients. Tarceva™ is an oral once-a-day small molecule drug designed to specifically block the activity of the HER1/EGFR protein and has demonstrated encouraging indications of anti-cancer activity in single-agent, open label Phase II trials in non-small cell lung cancer, head and neck cancer and ovarian cancer. Tarceva™ is being developed in an alliance with Genentech, Inc. and Roche and is currently in Phase III clinical trials for non-small cell lung cancer and pancreatic cancer.

58 South Service Road Suite 110
Melville, New York 11747
  (631) 962-2000
  info@osip.com

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.